Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study
Purpose: To characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG). Design: Prospective, multicenter real-world evidence study (CREST; NCT05506423 ). Participants: Adults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo™, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up. Methods: Adverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level. Main Outcome Measures: Pre-specified ocular safety endpoints: adverse events, clinically significant hypotony, sustained intraocular pressure (IOP) elevation ≥ 10 mmHg beyond 30 days, allograft migration, corneal endothelial decompensation, secondary incisional glaucoma surgery, and endothelial cell density. Results: Of 395 eyes (mean age 72.8 years; 52% female), 267 were combined with phacoemulsification (Cohort 1) and 128 standalone (Cohort 2). Medicated IOP decreased from 19.1 to 14.5 mmHg (p < 0.001) and medications from 1.9 to 1.2, with 42% medication-free. Sustained IOP elevation occurred in 34 eyes (8.6%), BCVA loss ≥ 2 lines in 15 (3.8%), hyphema > 2 mm in 6 (1.5%) and hypotony in 1 (0.3%). Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. Serious events occurred in 12 eyes (3.0%). In the N=91 eyes with paired specular microscopy data, endothelial cell density changed -6.5% (-8.7%, -4.4%). There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia. Conclusions: Through 12 months no endothelial decompensation, endophthalmitis or sympathetic ophthalmia occurred, and most events were self-limiting or medically managed. Endothelial cell loss tracked concurrent cataract surgery rather than the allograft, though that subgroup is small. Follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls.
Authors
- Tsontcho Ianchulev (ORCID: https://orcid.org/0000-0002-9893-5909)
- Douglas J. Rhee (ORCID: https://orcid.org/0000-0002-3459-7082)
- Steven R. Sarkisian (ORCID: https://orcid.org/0000-0001-7633-2720)
- Ticiana De Francesco (ORCID: https://orcid.org/0000-0002-0916-0911)
- James Lewis
- Kiper Nelson
Institutions
- University of Utah (US)
- New York Eye and Ear Infirmary (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-13
- DOI
- https://doi.org/10.64898/2026.11.12.26367928
- Primary Topic
- Glaucoma and retinal disorders
- Type
- preprint